NEJM This Week — April 23, 2026 @NEJMgroup

Uploaded April 2026 | Updated September 2026, 1 week ago

This week, we explore new strategies for blood-pressure control after intracerebral hemorrhage, Covid-19 treatment in higher-risk patients, hormonal therapy for prostate cancer, and anesthesia for tracheal intubation. We review spinal epidural abscess and follow a case of progressive weakness and liver lesions. We examine advances in tRNA research, and Perspectives discuss the use AI in prescribing, pediatric drug research, the impact of pharmaceutical mergers, and the goals of care.

NEJM Interview: Deirdre Tobias on the 2025–2030 Dietary Guidelines for Americans, including areas...

Case Record of the MGH: Cardiac Imaging in a Patient with Chest Pain and Dyspnea

NEJM Clinician: Catheter-Directed PE Treatment: Does it Deliver?

Clinical Decisions: Physical Examination for Asymptomatic Adults

NEJM Interview: Danielle Jones on the development of tools to help family physicians address soci...

NEJM Interview: Edward Ryan on factors driving continued disease and death from cholera and oppor...

Weave’s Brandon Rice on Rebuilding Drug Regulation with AI

$HFpEF Explained — Prevalence, New Advances, and How to Diagnose | NEJM This first episode of a three-part Double Take video miniseries on heart failure with preserved ejection fraction (HFpEF) from the New England Journal of Medicine discusses how HFpEF differs from heart failure with reduced ejection fraction, key risk factors, underlying causes, and the challenges of diagnosis. The cardiologists walk through the diagnostic evaluation, including use of the H2FPEF score to support clinical decision making. For further reading, the following articles, referenced in this video, are available at NEJM.org: Empagliflozin in Heart Failure with a Preserved Ejection Fraction (Anker et al., in the October 14, 2021, issue, https://www.nejm.org/doi/full/10.1056/NEJMoa2107038 ), Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (Kosiborod et al., in the September 21, 2023, issue, https://www.nejm.org/doi/full/10.1056/NEJMoa2306963 ), Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (Solomon et al., in the October 24, 2024, issue, https://www.nejm.org/doi/10.1056/NEJMoa2407107 ), Heart Failure with Preserved Ejection Fraction (Cannata and McDonagh, in the January 9, 2025, issue, https://www.nejm.org/doi/full/10.1056/NEJMcp2305181 ), and Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (Packer et al., in the January 30, 2025, issue, https://www.nejm.org/doi/full/10.1056/NEJMoa2410027 ). Funding for this Double Take is provided by the Doris Duke Foundation, committed to building a creative, equitable, and sustainable future. #medicaleducation #clinicalmedicine #nejm The New England Journal of Medicine is the world’s leading general medical journal. Continuously published for over 200 years, the Journal publishes peer-reviewed research along with interactive clinical content for physicians, educators, and the global medical community at NEJM.org.$